Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price

Celgene’s third-in-class CAR-T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) will be added to the NHI price list in Japan on May 19 at the same price as Kymriah’s (tisagenlecleucel) post cost-effectiveness assessment (CEA)-based adjustment price. Breyanzi’s listing was supported by...read more